## Lupin Prioritizes Sustainability: Developing Inhalers with Near-Zero Global Warming Potential Propellants
Lupin, a leading global pharmaceutical company, has announced its commitment to developing respiratory inhalers using propellants with near-zero global warming potential (GWP). This move signifies a significant step toward minimizing the environmental impact of essential medications, aligning with European regulations and Lupin’s dedication to sustainable healthcare practices.
This initiative will provide patients with pressurized metered dose inhalers (pMDIs) that maintain the same efficacy and safety while significantly reducing their carbon footprint. Professor Richard Dekhuijzen, a prominent pulmonologist at the Radboud University Medical Center in the Netherlands, emphasizes the dual benefit of this development: “The development of inhalers with near-zero global warming potential serves two major objectives: firstly, a maximal reduction of their environmental impact, and secondly, as important, keeping these medications available for those patients who really need these type of inhalers since they are unable to use dry powder inhalers.”
Lupin’s CEO, Vinita Gupta, underscores the company’s dedication to patient-centric innovation: “We are committed to making a positive impact in the lives of asthma patients worldwide. Our focus is on patient-centric sustainable healthcare innovation, ensuring that those who receive our pMDIs have reliable access to effective treatments with minimal impact to the environment.”
This innovative approach underscores Lupin’s commitment to environmental responsibility. The company acknowledges the environmental challenges impacting patients and communities, actively pursuing initiatives to minimize their footprint. By replacing standard propellants with near-zero GWP alternatives in their inhaler products, Lupin solidifies its position as a responsible pharmaceutical company, prioritizing both patient health and environmental sustainability.
About Lupin
Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical leader with a presence in over 100 markets. The company specializes in various pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers worldwide, Lupin holds a strong position in India and the U.S. across multiple therapeutic areas. With 15 state-of-the-art manufacturing sites, 7 research centers, and over 22,000 dedicated professionals, Lupin is committed to improving patient health outcomes through its subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
